Shares of ARCA biopharma, Inc. (ABIO) are trading 11 percent higher in pre-market after the company announced that the Data and Safety Monitoring Committee completed a pre-specified interim analysis and recommended completion of the Covid-19 treatment trial with no modifications to the trial design.
from RTT - Before the Bell https://ift.tt/3Gw57S1
via IFTTT
No comments:
Post a Comment